Indirect Encumbrance Created on Shares of Gujarat Themis Biosyn Limited Held by Pharmaceutical Business Group (India) Limited
Pharmaceutical Business Group (India) Limited (PBGIL), which holds a significant stake in Gujarat Themis Biosyn Limited (GTBL), has faced an indirect encumbrance on its equity shares. This development follows the creation of specific financial undertakings by Vividhmargi Investments Private Limited (VIPL) concerning its shareholding in PBGIL.The transaction involves VIPL creating two types of encumbrances over its holdings in PBGIL: a pledge and a non-disposal undertaking, as part of an agreement executed on June 28, 2026.
The specific details of the creation are as follows:
- A pledge was created over 25,24,245 equity shares of Pharmaceutical Business Group (India) Limited (PBGIL), which constitute 51% of PBGIL's issued and paid-up share capital.
- A non-disposal undertaking was placed on 21,57,855 equity shares of PBGIL, representing 47.98% of the issued and paid-up share capital of PBGIL.
This action by VIPL resulted in an indirect encumbrance being created over the shares of GTBL held by PBGIL.
Investor Holdings Summary
PBGIL maintains a substantial position in Gujarat Themis Biosyn Limited. As reported, PBGIL holds 5,12,40,000 equity shares of Gujarat Themis Biosyn Limited (GTBL), constituting 47.02% of the total equity share capital of the target company.The encumbrance event was documented on June 29, 2026, and is held in favour of CTL Trusteeship Limited, which is acting as the Debenture Trustee. The creation of this indirect encumbrance relates to PBGIL's holdings in GTBL.
GUJTHEM Stock Price Movement
Shares of Gujarat Themis Biosyn Limited are shedding value at 2:49 PM today, trading at ₹372.90 after slipping by 2.37%. The stock has registered a volume of 34,079 shares as it dips down by ₹9.05 from the previous close.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.